Hyperpigmentation

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Retrieved on:

Monday, March 25, 2024

Human, Obesity, Hyperpigmentation, Hunger, Patient, Sigma receptor, Polyphagia, Safety, Pharmacokinetics, SAD, MC4R, Pharmaceutical industry

BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the first patients have been dosed in the Company’s Phase 1 clinical trial of RM-718, an investigational, weekly melanocortin-4 receptor (MC4R)-specific agonist designed to be MC1R-sparing and to potentially avoid hyperpigmentation.

Key Points:

“We are excited to begin clinical development of RM-718, our next-generation MC4R agonist,” said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm.
In addition, RM-718 was designed to provide a weekly dosing regimen and to avoid hyperpigmentation.”
This Phase 1 trial is a three-part study to evaluate safety, tolerability and pharmacokinetics (PK).
Cohorts in Parts A and B are double-blind, placebo-controlled, and randomized 2:1.
Study participants will receive one weekly dose of either RM-718 or placebo in Part A, four weekly doses of either RM-718 or placebo in Part B, and four weekly doses of open-label RM-718 in Part C. RM-718 or placebo doses are administered weekly via subcutaneous injection.

Clinique Launches in the U.S. Amazon Premium Beauty Store

Retrieved on:

Wednesday, March 27, 2024

Clinique marks the first of a select few brands within The Estée Lauder Companies’ portfolio to open a storefront in the U.S. Amazon Premium Beauty store.

Key Points:

Clinique marks the first of a select few brands within The Estée Lauder Companies’ portfolio to open a storefront in the U.S. Amazon Premium Beauty store.
Developed with Clinique’s Guiding Dermatologists, this interactive questionnaire in Amazon Premium Beauty will custom-fit a skincare regimen for Clinique’s consumers, ensuring a simplified and personalized skincare journey, with recommended products available for purchase from Amazon’s Premium Beauty store.
“We are delighted to introduce Clinique to new consumers in the U.S and make it accessible for the beauty-savvy community in the Amazon Premium Beauty store,” said Michelle Freyre, Global Brand President, Clinique.
“Clinique is a beauty brand revered around the world, drawing on a rich heritage of dermatological expertise, and beloved across generations of customers,” said Melis del Rey, G.M., Amazon U.S. Stores Beauty, Baby, and Beauty Technology.

#PatThePeptide TikTok Challenge Sparks Surge in Demand: COSRX's The 6 Peptide Skin Booster Serum Sells Out Across Platforms within One Week

Retrieved on:

Wednesday, March 20, 2024

Cream, Absorption, Hyperpigmentation, Serum, Risk, Gland, Vitamin, Ulta, Skin, Irritation, Peptide, Vaccine

Aimed at spotlighting COSRX's hero product, The 6 Peptide Skin Booster Serum, the campaign shows how the brand has made skincare more accessible to everyone.

Key Points:

Aimed at spotlighting COSRX's hero product, The 6 Peptide Skin Booster Serum, the campaign shows how the brand has made skincare more accessible to everyone.
In response to overwhelming demand, COSRX TikTok Shop US and COSRX.com have announced that The 6 Peptide Skin Booster Serum is now back in stock.
"We are thrilled to witness the immense enthusiasm and passion generated by the #PatThePeptide TikTok challenge," said a COSRX representative.
The 6 Peptide Skin Booster Serum is currently available for purchase on COSRX TikTok Shop US and COSRX.com .

New Skincare and Makeup Launches from Indeed Labs™ All Under $30

Retrieved on:

Thursday, March 14, 2024

Cream, Interview, Red, Labs, Hyperpigmentation, Skin, Cosmetics

Each of these new releases upholds the brand's commitment to cruelty-free, fragrance-free formulations, responsibly sourced ingredients, and science-backed formulas.

Key Points:

Each of these new releases upholds the brand's commitment to cruelty-free, fragrance-free formulations, responsibly sourced ingredients, and science-backed formulas.
Beloved Nanoblur™ Blurring Cream has expanded into Nanoset™ Setting Spray, a makeup setting spray that instantly provides a photo-finish, matte look while locking in makeup and prolonging wear.
This setting and finishing spray instantly blurs pores and fine lines, and keeps makeup in place all day long giving camera-ready results, all while providing skincare benefits.
These hydrogel patches are a targeted, instant solution for tired, puffy-looking eyes without having to inject filler around the delicate eye area.

INTRODUCING BYOMA BODY

Retrieved on:

Wednesday, March 13, 2024

PHA, TIME, Face, Cell, Hyperpigmentation, Science, Microbiota, Complex, Inflammation, NMF, Dermis, Red, Skin, Ceramide, Love, BLUE, Irritation, BETA, Sphingolipid, Cholesterol, Dicarboxylic acid, Gland, Itch, Cosmetics

NEW YORK, March 13, 2024 /PRNewswire/ -- BYOMA BODY is here to disrupt and democratize the bodycare category in the same way we revolutionized skincare – bringing best-in-class barrier care and skin-compatible science below the neck. This is accessible, affordable, and approachable barrier care for the rest of you – targeted, clinically efficacious, sensorial formulas for your best body.

Key Points:

BYOMA Body is here to change that.
Skin does not have a uniform composition, so we are more likely to experience different issues on our body than on our faces.
BYOMA has carefully studied the science of skin – breaking down the barrier from the lipid layer to the microbiome.
This is a breakthrough in skin science that delivers the same level of care to your body as you show your face.

INTRODUCING BROWNKIND: SKINCARE DESIGNED FOR THE UNIQUE AGING SIGNS OF MELANIN-RICH SKIN

Retrieved on:

Tuesday, March 12, 2024

Dark, Cream, Hyperpigmentation, Gooseberry, Beauty, Cleanser, Trial of the century, Phyllanthus emblica, Skin, Dermatology, Love, Pathology, Multimedia, Ageing, Cosmetics

NEW YORK, March 12, 2024 /PRNewswire/ -- Today, brownkind proudly announces the launch of its revolutionary skincare line, dedicated to preserving the inherently youthful appearance of brown skin in every shade. With a deep understanding of the dermatological science of melanin-rich skin types (in all tones, from the lightest expression of melanin to black), brownkind seeks to redefine the standard of skincare for the unique concerns and signs of aging for melanin-rich skin.

Key Points:

With a deep understanding of the dermatological science of melanin-rich skin types (in all tones, from the lightest expression of melanin to black), brownkind seeks to redefine the standard of skincare for the unique concerns and signs of aging for melanin-rich skin.
"Skin of color has different signs of aging than white skin," said Dr. Gauri Desai.
It asks us to understand skin-care as an act of self-love, and to care for our skin with products that are scientifically designed for our specific concerns.
brownkind invites people of color to join us in celebrating the beauty of brown skin with our groundbreaking, melanin-targeted skincare line @brownkindskin.

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

Retrieved on:

Wednesday, March 6, 2024

Lentigo, Pigment, Metabolism, Melasma, Elasticity, UVR, Ageing, Patent, Phio Pharmaceuticals, Skin, Hyperpigmentation, Gene silencing, TYR, Downregulation and upregulation, Iodosobenzene, MMP1, Vaccine

The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins.

Key Points:

The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins.
Ultraviolet radiation (UVR) exposure is a known contributor to skin cancer and aging, inducing the hyperactivity of MMP1 which increases collagen breakdown and reduces collagen synthesis.
“We have a robust patent portfolio for Phio’s INTASYL siRNA technology,” said Robert Bitterman, CEO of Phio Pharmaceuticals.
“The addition of this recent patent grant for treatment of photodamaged skin is complementary to our current initiative in treating skin cancer.”

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on:

Thursday, February 22, 2024

-- Acquired global rights to oral MC4R agonist LB54640 from LG Chem --

Key Points:

ET --
BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023.
Fourth Quarter and Full Year 2023 Financial Results:
Cash Position: As of December 31, 2023, cash, cash equivalents and short-term investments were approximately $275.8 million, as compared to $333.3 million as of December 31, 2022.
S,G&A Expenses: S,G&A expenses were $32.4 million in the fourth quarter of 2023 and $117.5 million for the year ended December 31, 2023, compared to $26.3 million in the fourth quarter of 2022 and $92.0 million for the year ended December 31, 2022.
ET today to review its fourth quarter and year end 2023 financial results and recent business activities.

Dr. Suzan Obagi Appointed as Chief Medical Director at Obagi Cosmeceuticals, a Subsidiary of Waldencast plc.

Retrieved on:

Tuesday, February 20, 2024

Acne, WALD, Physician, Dermabrasion, Growth, Dermatology, Surgeon, Hyperpigmentation, Gold, Health, Patient, Laser, Pharmaceutical industry

Obagi is a subsidiary of Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform and publicly listed company.

Key Points:

Obagi is a subsidiary of Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform and publicly listed company.
Dr. Suzan Obagi is a world-renowned, leading board-certified dermatologist and cosmetic surgeon, recognized for her groundbreaking contributions to the fields of dermatology, cosmetic surgery, and skincare.
“I am thrilled to be taking on a more formal role at Obagi as the Company’s first-ever Chief Medical Director,” said Dr. Suzan Obagi.
"We are honored to deepen our relationship with Dr. Suzan Obagi as she assumes the role of Obagi’s inaugural Chief Medical Director," said Jordan Meyer, President of Obagi.

DermBiont Announces 2024 Development Pipeline Update for its First-in-Class Targeted Topical Therapeutics for Seborrheic Keratoses, Basal Cell Carcinomas, and Melasma

Retrieved on:

Thursday, February 22, 2024

DermBiont currently anticipates that data will be available in Q3 2024.

Key Points:

DermBiont currently anticipates that data will be available in Q3 2024.
SKs: DermBiont expects to report data from its CT-213 Phase 2b clinical trial of SM-020 gel 1.0% in Q3 2024.
BCCs and SCCISs: DermBiont expects to initiate its CT-217 Phase 2a clinical trial in Q1 2024 and report data in Q3 2024.
Melasma: DermBiont anticipates enrolling the first patient in its randomized, observer-blinded, vehicle-controlled CT-214 Phase 2b trial of SM-030 in 138 subjects with melasma in Q2 2024.